Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imaging BiometricsLSE:IBAI +3.23% EV-to-OCF is 12.52 as of Sep. 22, 2026. The stock has 4 warning signs investors should review. Among 685 Healthcare Providers & Services companies, Imaging Biometrics ranks worse than 56.93% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Imaging Biometrics's Enterprise Value is £1.92 Mil.
Imaging Biometrics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was £0.15 Mil. Therefore, Imaging Biometrics's EV-to-OCF for today is 12.52.
The historical rank and industry rank for Imaging Biometrics's EV-to-OCF or its related term are showing as below:
LSE:IBAI'
s EV-to-OCF Range Over the Past 10 Years
Min: -92.83 Med: -14.38 Max: 29.25
Current: 10.9
During the past 13 years, the highest EV-to-OCF of Imaging Biometrics was 29.25. The lowest was -92.83. And the median was -14.38.
LSE:IBAI's EV-to-OCF is ranked worse than 56.93% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 8.83
vs LSE:IBAI: 10.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imaging Biometrics's PE Ratio (TTM) for today is calculated as:
Imaging Biometrics's share price for today is £0.009.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imaging Biometrics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was £-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Imaging Biometrics EV-to-OCF Related Terms
Imaging Biometrics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Imaging Biometrics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Imaging Biometrics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imaging Biometrics EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Imaging Biometrics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Imaging Biometrics's EV-to-OCF falls into.
Imaging Biometrics's current Enterprise Value is £1.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imaging Biometrics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was £0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imaging Biometrics (LSE:IBAI) has a EV-to-OCF of 12.52 as of Sep. 22, 2026. According to the industry distribution chart, Imaging Biometrics ranks #390 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 56.9%.
Is Imaging Biometrics' EV-to-OCF too high?
Imaging Biometrics' current EV-to-OCF is 12.52. The Healthcare Providers & Services industry median EV-to-OCF is 8.83. Imaging Biometrics' value of 12.52 is 41.8% above this industry median. Based on the distribution chart, Imaging Biometrics ranks #390 out of 685 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Imaging Biometrics' EV-to-OCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Imaging Biometrics ranks #390 out of 685 companies for EV-to-OCF. This places Imaging Biometrics in the lower half of its industry. The industry median EV-to-OCF is 8.83. Imaging Biometrics' value of 12.52 is 41.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.83, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imaging Biometrics's current EV-to-OCF of 12.52 is 41.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imaging Biometrics's current EV-to-OCF is 12.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imaging Biometrics stock overvalued right now?
Imaging Biometrics (LSE:IBAI) has a current EV-to-OCF of 12.52. The current EV-to-OCF is 12.52 and 41.8% above the Healthcare Providers & Services industry median of 8.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Imaging Biometrics (LSE:IBAI), the current EV-to-OCF is 12.52 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imaging Biometrics Ltd formerly, IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on technologies. Its geographical segment includes United Kingdom, Switzerland, European Union, and the United States of America and reportable segments are holding company expenses, medical software, Oral GaM and organ-on-a-chip. The company derives a majority of its revenue from the United States of America. It also supplies medical technology solutions and has a neuroimaging product portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBAI has been successfully added to your 
